Andrew Justin Stewart Coats
Fondateur chez Actimed Therapeutics Ltd.
Profil
Andrew Justin Stewart Coats is the founder of Akamis Bio Ltd.
(founded in 2006) and Actimed Therapeutics Ltd.
(founded in 2017).
At Actimed Therapeutics Ltd., he is currently a Non-Executive Director.
Dr. Coats is currently the Chairman of MateraCor, Inc. and a Director at BioVentrix, Inc. He previously held positions as a Director at LoneStar Heart, Inc., Associate Medical Director at Royal Brompton Hospital NHS Trust National Heart & Lung Inst, Professor at The National Heart & Lung Institute, and Deputy Vice Chancellor at The University of Sydney.
Dr. Coats received a doctorate from Imperial College London and Oxford Colleges, and an MBA from London Business School.
Postes actifs de Andrew Justin Stewart Coats
| Sociétés | Poste | Début |
|---|---|---|
Actimed Therapeutics Ltd.
 Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Fondateur | 01/01/2017 |
MateraCor, Inc.
 MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Président | - |
BioVentrix, Inc.
 BioVentrix, Inc. Medical SpecialtiesHealth Technology BioVentrix, Inc. engages in development of medical devices. It offers Less Invasive Ventricular Enhancement, or the LIVE therapy, which uses the Revivent TC transcatheter ventricular enhancement system to exclude scar tissue on the left ventricle that has occurred from a heart attack. The company was founded by Arthur A. Bertolero and Lon S. Annest in 2003 and is headquartered in San Ramon, CA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Andrew Justin Stewart Coats
| Sociétés | Poste | Fin |
|---|---|---|
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Fondateur | - |
| The University of Sydney | Corporate Officer/Principal | - |
The National Heart & Lung Institute
 The National Heart & Lung Institute Miscellaneous Commercial ServicesCommercial Services The National Heart & Lung Institute provided medical educational services. The company was headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
| Royal Brompton Hospital NHS Trust National Heart & Lung Inst | Corporate Officer/Principal | - |
LoneStar Heart, Inc.
 LoneStar Heart, Inc. Miscellaneous Commercial ServicesCommercial Services LoneStar Heart, Inc. develops cardiac restorative therapies for patients with heart failure. The firm functions in collaboration with the Texas Heart Institute, the University of Texas Southwestern Medical Center and a global network of leading clinicians. Its flagship product is Algisyl-LVR, a medical device under clinical development intended to prevent or reverse the progression of advanced heart failure in patients who have an enlarged left ventricle. The company was founded in June 2010 by James T. Willerson, Eric N. Olson and Olav B. Bergheim and is headquartered in Laguna Hills, CA. | Directeur/Membre du Conseil | - |
Formation de Andrew Justin Stewart Coats
| Imperial College London | Doctorate Degree |
| Oxford Colleges | Doctorate Degree |
| London Business School | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
BioVentrix, Inc.
BioVentrix, Inc. Medical SpecialtiesHealth Technology BioVentrix, Inc. engages in development of medical devices. It offers Less Invasive Ventricular Enhancement, or the LIVE therapy, which uses the Revivent TC transcatheter ventricular enhancement system to exclude scar tissue on the left ventricle that has occurred from a heart attack. The company was founded by Arthur A. Bertolero and Lon S. Annest in 2003 and is headquartered in San Ramon, CA. | Health Technology |
LoneStar Heart, Inc.
LoneStar Heart, Inc. Miscellaneous Commercial ServicesCommercial Services LoneStar Heart, Inc. develops cardiac restorative therapies for patients with heart failure. The firm functions in collaboration with the Texas Heart Institute, the University of Texas Southwestern Medical Center and a global network of leading clinicians. Its flagship product is Algisyl-LVR, a medical device under clinical development intended to prevent or reverse the progression of advanced heart failure in patients who have an enlarged left ventricle. The company was founded in June 2010 by James T. Willerson, Eric N. Olson and Olav B. Bergheim and is headquartered in Laguna Hills, CA. | Commercial Services |
| Royal Brompton Hospital NHS Trust National Heart & Lung Inst | Health Services |
The National Heart & Lung Institute
The National Heart & Lung Institute Miscellaneous Commercial ServicesCommercial Services The National Heart & Lung Institute provided medical educational services. The company was headquartered in London, the United Kingdom. | Commercial Services |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Actimed Therapeutics Ltd.
Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Commercial Services |
MateraCor, Inc.
MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Health Technology |